When is an anthracycline‑containing regimen indicated for early‑stage high‑risk breast cancer, and what is the recommended dosing schedule?

Anthracycline-Containing Regimens for Early-Stage High-Risk Breast Cancer

For high-risk early breast cancer, sequential anthracycline-taxane regimens remain the standard of care and provide superior outcomes compared to non-anthracycline alternatives, particularly in patients with triple-negative disease, HER2-positive disease, or genomic high-risk features (21-gene recurrence score ≥31). 1, 2

Indications for Anthracycline-Based Chemotherapy

A sequential anthracycline/taxane-based regimen is the standard for the majority of patients with early-stage high-risk breast cancer. 1

Specific High-Risk Populations Where Anthracyclines Are Strongly Indicated:

• Triple-negative breast cancer regardless of nodal status 3
• HER2-positive, node-positive disease (retrospective evidence suggests anthracyclines may be superior in HER2-positive tumors) 4
• Hormone receptor-positive/HER2-negative disease with significant nodal involvement 3
• Genomic high-risk disease with 21-gene recurrence score ≥31 (anthracyclines provide significant benefit: 5-year DRFI 96.1% with anthracycline-taxane vs 91.0% with taxane-cyclophosphamide alone, aHR 0.31, P=0.006) 5

Patients Where Anthracyclines May Be Omitted:

• Low-risk, node-negative disease (consider TC or CMF regimens) 1, 3
• Patients at high cardiac risk (non-anthracycline regimens should be used) 1
• Selected HER2-positive, low-risk stage I disease (paclitaxel plus trastuzumab may be considered) 4, 3

Recommended Dosing Schedules

Preferred Anthracycline-Taxane Regimens:

AC followed by paclitaxel (dose-dense):

• Doxorubicin 60 mg/m² IV day 1 + cyclophosphamide 600 mg/m² IV day 1, every 14 days × 4 cycles
• Followed by paclitaxel 175 mg/m² IV over 3 hours, every 14 days × 4 cycles
• All cycles require G-CSF support 6, 7

AC followed by weekly paclitaxel:

• Doxorubicin 60 mg/m² IV day 1 + cyclophosphamide 600 mg/m² IV day 1, every 21 days × 4 cycles
• Followed by paclitaxel 80 mg/m² IV weekly × 12 weeks 4, 7

TAC regimen:

• Docetaxel 75 mg/m² IV day 1 + doxorubicin 50 mg/m² IV day 1 + cyclophosphamide 500 mg/m² IV day 1
• Every 21 days × 6 cycles with G-CSF support 4, 6

FEC followed by docetaxel:

• Fluorouracil 500 mg/m² + epirubicin 100 mg/m² + cyclophosphamide 500 mg/m² every 21 days × 3 cycles
• Followed by docetaxel 100 mg/m² every 21 days × 3 cycles 7

Optimal Cumulative Anthracycline Dosing:

For patients with high-risk disease not receiving a taxane, use optimal-dose anthracycline regimens:

• Cumulative doxorubicin dose ≥240 mg/m² (but not exceeding 240 mg/m² in two-drug regimens) 7
• Cumulative epirubicin dose ≥600 mg/m² but not >720 mg/m² 7

Anthracycline-based regimens should preferably not include 5-FU; EC or AC are the standard. 1

Dose-Dense Scheduling

Dose-dense schedules with G-CSF support should be considered, particularly in highly proliferative tumors. 1 Patient-level meta-analysis demonstrates that dose-dense chemotherapy is associated with significant reduction in breast cancer recurrences and mortality compared to conventional scheduling 8.

Duration of Treatment

Chemotherapy should be administered for 12-24 weeks (four to eight cycles). 1

Critical Sequencing Considerations

All chemotherapy regimens should be given before radiotherapy (exception: CMF may be given concurrently with radiation or first). 4, 6

Chemotherapy and endocrine therapy should be given sequentially, with endocrine therapy after chemotherapy. 4, 6

HER2-Positive Disease Specific Considerations

Trastuzumab should not be given concurrently with anthracyclines due to significant cardiac toxicity. 4, 1 Trastuzumab should optimally be given concurrently with paclitaxel as part of the AC followed by paclitaxel regimen, and continued for 1 year total duration 4.

For HER2-positive disease, preferred regimens include:

• AC followed by paclitaxel plus trastuzumab ± pertuzumab 4
• Pertuzumab should be added for node-positive or ER-negative, HER2-positive disease for 1 year duration 1

Evidence Supporting Anthracycline Use

The most recent and comprehensive evidence comes from a 2023 patient-level meta-analysis of 100,000 women from 86 randomized trials, which demonstrated that anthracycline-taxane chemotherapy substantially improves survival compared to taxane alone, with 14% lower recurrence rates (RR 0.86,95% CI 0.79-0.93; p=0.0004). 2 The clearest benefit was seen when anthracycline was added concurrently to docetaxel plus cyclophosphamide (10-year recurrence risk 12.3% vs 21.0%; RR 0.58, p<0.0001) 2.

Higher cumulative doses and more dose-intense schedules of anthracycline-taxane regimens provide the greatest benefits, challenging the current trend toward shorter non-anthracycline regimens such as four cycles of docetaxel-cyclophosphamide 2.

Important Caveats

Maintaining relative dose intensity (RDI) ≥90% is critical for optimal outcomes. RDI <90% is associated with significantly worse overall survival (P=0.006) in multivariate analysis 9. Every effort should be made to avoid unnecessary dose reductions or treatment interruptions 9.

Monitor for anthracycline-related toxicities: approximately one additional acute myeloid leukemia case occurs per 700 women treated 2. Cardiac monitoring is mandatory, particularly when combining with HER2-targeted therapies 1.